MaxCyte And Vittoria Biotherapeutics Sign Strategic Platform License To Advance Next Generation Cellular Therapies
Portfolio Pulse from Happy Mohamed
MaxCyte, Inc. (NASDAQ:MXCT) and Vittoria Biotherapeutics have signed a strategic platform license (SPL) for MaxCyte's Flow Electroporation technology and ExPERT platform. Vittoria will obtain non-exclusive clinical and commercial rights to use the technology and platform, while MaxCyte will receive licensing fees and program-related revenue. Vittoria plans to file an investigational new drug application for their lead program, Viper 101, later this year.
July 10, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MaxCyte's partnership with Vittoria Biotherapeutics could lead to increased licensing fees and program-related revenue. The deal also provides an opportunity for MaxCyte to further validate and showcase its technology.
The strategic platform license agreement with Vittoria Biotherapeutics allows MaxCyte to monetize its Flow Electroporation technology and ExPERT platform through licensing fees and program-related revenue. This partnership also provides an opportunity for MaxCyte to further validate and showcase its technology in the field of CAR-T therapies, which could potentially lead to more partnerships and revenue in the future.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100